Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase
- 9 December 1999
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (1) , 133-138
- https://doi.org/10.1021/jm990401t
Abstract
4-Anilinoquinazolines represent an important class of protein kinase inhibitor. Modes of binding for two members of this inhibitor class were determined by X-ray crystallographic analysis of one inhibitor (4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline) in complex with cyclin-dependent kinase 2 (CDK2) and the other (4-[3-methylsulfanylanilino]-6,7-dimethoxyquinazoline) in complex with p38 kinase. In both inhibitor/kinase structures, the 4-anilinoquinazoline was bound in the ATP site with the quinazoline ring system oriented along the peptide strand that links the two domains of the protein and with the anilino substituent projecting into a hydrophobic pocket within the protein interior. In each case, the nitrogen at position-1 of the quinazoline accepted a hydrogen bond from a backbone NH (CDK2, Leu-83; p38, Met-109) of the domain connector strand, and aromatic hydrogen atoms at C2 and C8 interacted with backbone carbonyl oxygen atoms of the peptide strand. The anilino group of the CDK2-bound compound was essentially coplanar with the quinazoline ring system and occupied a pocket between Lys-33 and Phe-80. For the p38-bound inhibitor, the anilino group was angled out of plane and was positioned between Lys-53 and Thr-106 in a manner similar to that observed for the aryl substituent of the pyridinylimidazole class of inhibitor.Keywords
This publication has 26 references indexed in Scilit:
- CYCLIN-DEPENDENT KINASES: Engines, Clocks, and MicroprocessorsAnnual Review of Cell and Developmental Biology, 1997
- Protein tyrosine kinase inhibitors in cancer treatmentExpert Opinion on Therapeutic Patents, 1997
- Inhibition of Cyclin‐Dependent Kinases by Purine AnaloguesEuropean Journal of Biochemistry, 1997
- Improved Structure Refinement Through Maximum LikelihoodActa Crystallographica Section A Foundations of Crystallography, 1996
- Protein kinase inhibitors for the treatment of cancerDrug Discovery Today, 1996
- STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITROClinical and Experimental Pharmacology and Physiology, 1996
- Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolinesBreast Cancer Research and Treatment, 1996
- Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complexNature, 1995
- Free R value: a novel statistical quantity for assessing the accuracy of crystal structuresNature, 1992
- Chiral trialkylborane reducing agents. Preparation of 1-deuterio primary alcohols of high enantiomeric purityJournal of the American Chemical Society, 1979